326 related articles for article (PubMed ID: 7796391)
41. [Genetic basis of malignant melanoma].
Drewa G; Powierska-Czarny J
Postepy Hig Med Dosw; 1998; 52(4):367-80. PubMed ID: 9780757
[TBL] [Abstract][Full Text] [Related]
42. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
Zheng J; Hou P; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
[TBL] [Abstract][Full Text] [Related]
43. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
44. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
Hirama T; Miller CW; Wilczynski SP; Koeffler HP
Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
[TBL] [Abstract][Full Text] [Related]
45. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
46. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
[TBL] [Abstract][Full Text] [Related]
47. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
Koh J; Enders GH; Dynlacht BD; Harlow E
Nature; 1995 Jun; 375(6531):506-10. PubMed ID: 7777061
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
[TBL] [Abstract][Full Text] [Related]
49. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
50. A novel p16INK4A transcript.
Mao L; Merlo A; Bedi G; Shapiro GI; Edwards CD; Rollins BJ; Sidransky D
Cancer Res; 1995 Jul; 55(14):2995-7. PubMed ID: 7541708
[TBL] [Abstract][Full Text] [Related]
51. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes.
Curry JL; Richards HW; Huttenbach YT; Medrano EE; Reed JA
J Cutan Pathol; 2009 Feb; 36(2):197-205. PubMed ID: 18647205
[TBL] [Abstract][Full Text] [Related]
52. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
Sparrow LE; Eldon MJ; English DR; Heenan PJ
Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
[TBL] [Abstract][Full Text] [Related]
53. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.
Easty DJ; Guthrie BA; Maung K; Farr CJ; Lindberg RA; Toso RJ; Herlyn M; Bennett DC
Cancer Res; 1995 Jun; 55(12):2528-32. PubMed ID: 7780963
[TBL] [Abstract][Full Text] [Related]
54. [p16/CDKN2/MTS1 gene abnormality in lung cancer].
Ohno A
Nihon Rinsho; 1996 Feb; 54(2):503-6. PubMed ID: 8838105
[TBL] [Abstract][Full Text] [Related]
55. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma.
Funk JO; Schiller PI; Barrett MT; Wong DJ; Kind P; Sander CA
J Cutan Pathol; 1998 Jul; 25(6):291-6. PubMed ID: 9694617
[TBL] [Abstract][Full Text] [Related]
56. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells.
Jagasia AA; Sher DA; Le Moine PJ; Kim DH; Moldwin RL; Smith SD; Diaz MO
Leukemia; 1996 Apr; 10(4):624-8. PubMed ID: 8618438
[TBL] [Abstract][Full Text] [Related]
57. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
[TBL] [Abstract][Full Text] [Related]
58. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
59. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
Gruis NA; van der Velden PA; Sandkuijl LA; Prins DE; Weaver-Feldhaus J; Kamb A; Bergman W; Frants RR
Nat Genet; 1995 Jul; 10(3):351-3. PubMed ID: 7670475
[TBL] [Abstract][Full Text] [Related]
60. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
